Roche Holding AG
RO
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Stocks News & Analysis
stocks
6 undervalued stocks with low beta
Berkshire Hathaway and Verizon are among the low-volatility stocks that trade at a discount.
stocks
An undervalued, wide-moat name in healthcare
Companies racing for a coronavirus cure have moved to lofty valuations. Morningstar analyst Alex Morozov is looking for lesser-known healthcare names.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,052.70 | 80.40 | -0.99% |
| CAC 40 | 7,598.98 | 259.85 | -3.31% |
| DAX 40 | 21,717.39 | 673.45 | -3.01% |
| Dow JONES (US) | 40,561.06 | 1,664.26 | -3.94% |
| FTSE 100 | 8,474.74 | 133.74 | -1.55% |
| HKSE | 22,849.81 | 352.72 | -1.52% |
| NASDAQ | 16,566.95 | 1,034.09 | -5.88% |
| Nikkei 225 | 34,735.93 | 989.94 | -2.77% |
| NZX 50 Index | 12,338.57 | 18.38 | 0.15% |
| S&P 500 | 5,399.49 | 271.48 | -4.79% |
| S&P/ASX 200 | 7,859.70 | 74.80 | -0.94% |
| SSE Composite Index | 3,342.01 | 8.12 | -0.24% |